Difference between revisions of "Part:BBa K1699001:Experience"
| Line 2: | Line 2: | ||
| − | This part is an improvement of existing part [https://parts.igem.org/Part:BBa_K404106] due to the following reasons: | + | This part is an improvement of existing part BBa_K404106 [https://parts.igem.org/Part:BBa_K404106] due to the following reasons: |
1. Our part is shorter (378 bp vs 459 bp), thus permitting more flexible design in various scenarios when length could be a critical issue. | 1. Our part is shorter (378 bp vs 459 bp), thus permitting more flexible design in various scenarios when length could be a critical issue. | ||
| + | |||
2. Our part adds extensive characterization results in human cancer cells, showing data of promoter validation, and, importantly, functional data where hTERT promoter was used to successfully control the expression of dCas9-VP64 in cancer-specific CRIPSR-based activation system. In the original part, actual experimental data is missing. | 2. Our part adds extensive characterization results in human cancer cells, showing data of promoter validation, and, importantly, functional data where hTERT promoter was used to successfully control the expression of dCas9-VP64 in cancer-specific CRIPSR-based activation system. In the original part, actual experimental data is missing. | ||
| + | |||
3. The design summary of hTERT promoter in cancer-specific CRISPR-based gene knock-out is also shown, further expanding the usability of the part. | 3. The design summary of hTERT promoter in cancer-specific CRISPR-based gene knock-out is also shown, further expanding the usability of the part. | ||
Latest revision as of 10:11, 13 September 2015
This part is an improvement of existing part BBa_K404106 [1] due to the following reasons:
1. Our part is shorter (378 bp vs 459 bp), thus permitting more flexible design in various scenarios when length could be a critical issue.
2. Our part adds extensive characterization results in human cancer cells, showing data of promoter validation, and, importantly, functional data where hTERT promoter was used to successfully control the expression of dCas9-VP64 in cancer-specific CRIPSR-based activation system. In the original part, actual experimental data is missing.
3. The design summary of hTERT promoter in cancer-specific CRISPR-based gene knock-out is also shown, further expanding the usability of the part.
Applications of BBa_K1699001
User Reviews
UNIQf43381b709a1e428-partinfo-00000000-QINU UNIQf43381b709a1e428-partinfo-00000001-QINU